Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 5/20 | 0.56 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | OGA | O60502 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958994 | 0.82 | HRH4 (0.56) | ACHEOGAHRH3 | |
| SCHEMBL4948656 | 0.82 | HRH4 (0.56) | ACHEOGAHRH3 | |
| SCHEMBL5458684 | 0.81 | OGA (0.44) | ACHEPTPN11LMNAOGA | |
| SCHEMBL4498304 | 0.79 | OGA (0.48) | ACHEMAPTOGA | |
| SCHEMBL15740608 | 0.79 | OGA (0.42) | ACHELMNAOGA | |
| SCHEMBL3910170 | 0.79 | LMNA (0.57) | ACHELMNAMAPTDRD2SIGMAR1 | |
| SCHEMBL4947574 | 0.77 | KDM1A (0.48) | ACHEOGA | |
| SCHEMBL10187275 | 0.77 | KDM1A (0.48) | ACHEOGA | |
| SCHEMBL9900073 | 0.75 | KDM1A (0.47) | ACHEOGA | |
| SCHEMBL5452265 | 0.74 | DRD2 (0.50) | LMNADRD2SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | ACHE 1245/4885PTPN11 888/4885LMNA 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.